Review



custom oligonucleotide pools  (Twist Bioscience)


Bioz Verified Symbol Twist Bioscience is a verified supplier
Bioz Manufacturer Symbol Twist Bioscience manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Twist Bioscience custom oligonucleotide pools
    Custom Oligonucleotide Pools, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/Custom+Pools/pm42608566-565-0-13
    Average 94 stars, based on 1 article reviews
    custom oligonucleotide pools - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    Library Amplification:

    Article Title: Scalable generation and functional classification of genetic variants in inborn errors of immunity to accelerate clinical diagnosis and treatment
    Article Snippet: .. 7 Custom oligonucleotide pools (Twist Bioscience) encoding the individual sgRNA sequences and flanking regions for library amplification and cloning were used for pooled golden-gate cloning of sgRNA gene editing libraries into the CropSeq vector as previously described. .. T cells were then plated in flat-bottom 96-well plates at 100,000 T cells per well with 1:100 v/v LentiBOOST transduction enhancer (Mayflower Biosciences, # SBPLV10112) and 1:10 v/v of 10x concentrated lentivirus.

    Cloning:

    Article Title: Scalable generation and functional classification of genetic variants in inborn errors of immunity to accelerate clinical diagnosis and treatment
    Article Snippet: .. 7 Custom oligonucleotide pools (Twist Bioscience) encoding the individual sgRNA sequences and flanking regions for library amplification and cloning were used for pooled golden-gate cloning of sgRNA gene editing libraries into the CropSeq vector as previously described. .. T cells were then plated in flat-bottom 96-well plates at 100,000 T cells per well with 1:100 v/v LentiBOOST transduction enhancer (Mayflower Biosciences, # SBPLV10112) and 1:10 v/v of 10x concentrated lentivirus.

    Article Title: Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells
    Article Snippet: .. Custom oligonucleotide pools (TWIST Bioscience) encoding the individual sgRNA sequences and flanking regions for targeted subpool amplification and cloning were used for pooled golden-gate cloning of sgRNA gene editing libraries into the CropSeq vector as previously described( ). ..

    Plasmid Preparation:

    Article Title: Scalable generation and functional classification of genetic variants in inborn errors of immunity to accelerate clinical diagnosis and treatment
    Article Snippet: .. 7 Custom oligonucleotide pools (Twist Bioscience) encoding the individual sgRNA sequences and flanking regions for library amplification and cloning were used for pooled golden-gate cloning of sgRNA gene editing libraries into the CropSeq vector as previously described. .. T cells were then plated in flat-bottom 96-well plates at 100,000 T cells per well with 1:100 v/v LentiBOOST transduction enhancer (Mayflower Biosciences, # SBPLV10112) and 1:10 v/v of 10x concentrated lentivirus.

    Article Title: Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells
    Article Snippet: .. Custom oligonucleotide pools (TWIST Bioscience) encoding the individual sgRNA sequences and flanking regions for targeted subpool amplification and cloning were used for pooled golden-gate cloning of sgRNA gene editing libraries into the CropSeq vector as previously described( ). ..

    Synthesized:

    Article Title: Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.
    Article Snippet: The medium was aspirated from cells and cells were lysed by adding 200 μl of 1× Laemmli buffer (BioRad, 1610747) + 1% β-mercaptoethanol (Millipore Sigma, 63689-25ML-F) directly to the well. .. Custom oligonucleotide pools, incorporating additional nucleotides containing the BsmBI-v2 recognition site, were synthesized (Twist Bioscience). .. Then, 25 μl of each sample was loaded on a NuPAGE Bis–Tris 4–12% gradient gel (Thermo Fisher) and separated by SDS–PAGE in 1× NuPAGE MOPS running buffer (Thermo Fisher, NP0001) at a constant voltage of 150 V for 1 h. Proteins were transferred onto a PVDF membrane using Trans-Blot Turbo mini PVDF transfer packs according to the manufacturer’s protocol (BioRad, 1704156).

    Amplification:

    Article Title: Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells
    Article Snippet: .. Custom oligonucleotide pools (TWIST Bioscience) encoding the individual sgRNA sequences and flanking regions for targeted subpool amplification and cloning were used for pooled golden-gate cloning of sgRNA gene editing libraries into the CropSeq vector as previously described( ). ..

    Article Title: Single-molecule spatial genomics reveals the multi-scale organization and plasticity of extrachromosomal DNA in glioblastoma
    Article Snippet: These were purchased from IDT with high-performance liquid chromatography (HPLC) purification. .. In brief, the custom oligonucleotide pools (Twist Biosciences) were subjected to limited-cycle PCR amplification, during which a 5′-acrydite–modified forward primer was incorporated to facilitate subsequent integration into an acrylamide gel. .. The resulting amplified DNA served as the template for in vitro transcription using T7 polymerase (NEB), followed by reverse transcription with Maxima RT (Thermo Scientific) and hydrolysis of the RNA strand to produce single-stranded DNA probes.

    Polymerase Chain Reaction:

    Article Title: Single-molecule spatial genomics reveals the multi-scale organization and plasticity of extrachromosomal DNA in glioblastoma
    Article Snippet: These were purchased from IDT with high-performance liquid chromatography (HPLC) purification. .. In brief, the custom oligonucleotide pools (Twist Biosciences) were subjected to limited-cycle PCR amplification, during which a 5′-acrydite–modified forward primer was incorporated to facilitate subsequent integration into an acrylamide gel. .. The resulting amplified DNA served as the template for in vitro transcription using T7 polymerase (NEB), followed by reverse transcription with Maxima RT (Thermo Scientific) and hydrolysis of the RNA strand to produce single-stranded DNA probes.

    Acrylamide Gel Assay:

    Article Title: Single-molecule spatial genomics reveals the multi-scale organization and plasticity of extrachromosomal DNA in glioblastoma
    Article Snippet: These were purchased from IDT with high-performance liquid chromatography (HPLC) purification. .. In brief, the custom oligonucleotide pools (Twist Biosciences) were subjected to limited-cycle PCR amplification, during which a 5′-acrydite–modified forward primer was incorporated to facilitate subsequent integration into an acrylamide gel. .. The resulting amplified DNA served as the template for in vitro transcription using T7 polymerase (NEB), followed by reverse transcription with Maxima RT (Thermo Scientific) and hydrolysis of the RNA strand to produce single-stranded DNA probes.



    Similar Products

    94
    Lee Biosolutions pooled human saliva
    Pooled Human Saliva, supplied by Lee Biosolutions, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/Saliva%2C+Pooled+Human+Donors/10__1021_slash_acsnano__6c12112-167-23-29
    Average 94 stars, based on 1 article reviews
    pooled human saliva - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    99
    ATCC primary human umbilical vein ecs
    Primary Human Umbilical Vein Ecs, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human%2C+Pooled/10__1007_slash_s12195___026___00963___5-44-0-6
    Average 99 stars, based on 1 article reviews
    primary human umbilical vein ecs - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Sony Biotechnology cd4 car tcd19 ngfr t cell pools
    (A) Barcode level CD8 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD8 + screen. (B) and (C) <t>CD4</t> + log 2 fold change relative to the frequency in the plasmid pool (Day −10) vs. time for bZIP variants significantly enriched (B) or de-enriched (C) in CD8 + <t>T</t> <t>cells.</t> Log 2 fold change fit by n = 2 donors, 2 replicates and calculated via DESeq2; significance calculated via Wald test in DESeq2. Open circles indicate timepoints with p adj < 0.05. (D) Barcode level CD4 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD4 + screen. The results from one bZIP screen replicate on two donors are shown in (A) and (D).
    Cd4 Car Tcd19 Ngfr T Cell Pools, supplied by Sony Biotechnology, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/SH800+Cell+Sorter/bio_rxiv__64898__2026__10__28__762687-339-3-15
    Average 99 stars, based on 1 article reviews
    cd4 car tcd19 ngfr t cell pools - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC huvec pcs 100 013 cell lines
    (A) Barcode level CD8 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD8 + screen. (B) and (C) <t>CD4</t> + log 2 fold change relative to the frequency in the plasmid pool (Day −10) vs. time for bZIP variants significantly enriched (B) or de-enriched (C) in CD8 + <t>T</t> <t>cells.</t> Log 2 fold change fit by n = 2 donors, 2 replicates and calculated via DESeq2; significance calculated via Wald test in DESeq2. Open circles indicate timepoints with p adj < 0.05. (D) Barcode level CD4 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD4 + screen. The results from one bZIP screen replicate on two donors are shown in (A) and (D).
    Huvec Pcs 100 013 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/Primary+Umbilical+Vein+Endothelial+Cells%3B+Normal%2C+Human%2C+Pooled/pm42951958-615-14-21
    Average 99 stars, based on 1 article reviews
    huvec pcs 100 013 cell lines - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Twist Bioscience oligo pool
    (A) Barcode level CD8 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD8 + screen. (B) and (C) <t>CD4</t> + log 2 fold change relative to the frequency in the plasmid pool (Day −10) vs. time for bZIP variants significantly enriched (B) or de-enriched (C) in CD8 + <t>T</t> <t>cells.</t> Log 2 fold change fit by n = 2 donors, 2 replicates and calculated via DESeq2; significance calculated via Wald test in DESeq2. Open circles indicate timepoints with p adj < 0.05. (D) Barcode level CD4 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD4 + screen. The results from one bZIP screen replicate on two donors are shown in (A) and (D).
    Oligo Pool, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/Oligo+Pools/pm42916580-52-10-13
    Average 99 stars, based on 1 article reviews
    oligo pool - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    97
    MedChemExpress cell pool
    CRISPRa integration with TCGA TARGET GTEx database for identifying <t>sorafenib</t> DS-related genes and constructing a novel prognostic signature. A Schematic outline of the CRISPRa screen. SNU387 cells were infected with lenti-MPHv2 lentivirus and then selected with hygromycin (200 µg/mL). Subsequently, the library containing cell pool was constructed by infecting with the SAM libraries lentivirus at an MOI = 0.3 and selecting with blasticidin (3 µg/mL). The cell pool was treated with DMSO or sorafenib (7µM) and 2 weeks post-treatment, surviving cells were subjected to NGS to identify the relative enrichment or depletion of sgRNAs between two groups. B Venn plot showed the intersections genes between top 200 positive selection from CRISPRa screen and up-regulated DEGs between tumor and normal tissues in liver. C Heatmap displayed expression level of these 13 genes in HCC and normal tissues. D KEGG pathways of these 13 genes were rank-ordered by enrichment ratio. E Forest plot of P value and HR for 13 sorafenib DS-related genes. P < 0.05 was considered statistically significant. Protective factor: HR < 1; Risk factor: HR > 1. F LASSO regression analysis of these 5 sorafenib DS-related prognostic genes. Red dots representing partial likelihood deviance values and error bars representing standard error (SE). The left and right dotted lines represented optimal values by minimum criteria and 1SE criteria, respectively. G LASSO coefficient profiles of the 5 sorafenib DS-related prognostic genes. H Left: flowchart for prognostic model establishment. Right: the distributions of risk score and survival status of 5 sorafenib DS-related prognosis signature genes for TCGA-LIHC dataset. I Heatmap showed high expression of 5 sorafenib DS-related prognostic genes in high-risk populations. J Violin plot compared risk score between High-risk and Low-risk patients
    Cell Pool, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/Sorafenib/pmc13753384-41-23-34
    Average 97 stars, based on 1 article reviews
    cell pool - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    99
    Twist Bioscience oligonucleotide pool
    CRISPRa integration with TCGA TARGET GTEx database for identifying <t>sorafenib</t> DS-related genes and constructing a novel prognostic signature. A Schematic outline of the CRISPRa screen. SNU387 cells were infected with lenti-MPHv2 lentivirus and then selected with hygromycin (200 µg/mL). Subsequently, the library containing cell pool was constructed by infecting with the SAM libraries lentivirus at an MOI = 0.3 and selecting with blasticidin (3 µg/mL). The cell pool was treated with DMSO or sorafenib (7µM) and 2 weeks post-treatment, surviving cells were subjected to NGS to identify the relative enrichment or depletion of sgRNAs between two groups. B Venn plot showed the intersections genes between top 200 positive selection from CRISPRa screen and up-regulated DEGs between tumor and normal tissues in liver. C Heatmap displayed expression level of these 13 genes in HCC and normal tissues. D KEGG pathways of these 13 genes were rank-ordered by enrichment ratio. E Forest plot of P value and HR for 13 sorafenib DS-related genes. P < 0.05 was considered statistically significant. Protective factor: HR < 1; Risk factor: HR > 1. F LASSO regression analysis of these 5 sorafenib DS-related prognostic genes. Red dots representing partial likelihood deviance values and error bars representing standard error (SE). The left and right dotted lines represented optimal values by minimum criteria and 1SE criteria, respectively. G LASSO coefficient profiles of the 5 sorafenib DS-related prognostic genes. H Left: flowchart for prognostic model establishment. Right: the distributions of risk score and survival status of 5 sorafenib DS-related prognosis signature genes for TCGA-LIHC dataset. I Heatmap showed high expression of 5 sorafenib DS-related prognostic genes in high-risk populations. J Violin plot compared risk score between High-risk and Low-risk patients
    Oligonucleotide Pool, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/Oligo+Pools/pm42901160-779-1-6
    Average 99 stars, based on 1 article reviews
    oligonucleotide pool - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Twist Bioscience rn1 ssdna oligo pools
    CRISPRa integration with TCGA TARGET GTEx database for identifying <t>sorafenib</t> DS-related genes and constructing a novel prognostic signature. A Schematic outline of the CRISPRa screen. SNU387 cells were infected with lenti-MPHv2 lentivirus and then selected with hygromycin (200 µg/mL). Subsequently, the library containing cell pool was constructed by infecting with the SAM libraries lentivirus at an MOI = 0.3 and selecting with blasticidin (3 µg/mL). The cell pool was treated with DMSO or sorafenib (7µM) and 2 weeks post-treatment, surviving cells were subjected to NGS to identify the relative enrichment or depletion of sgRNAs between two groups. B Venn plot showed the intersections genes between top 200 positive selection from CRISPRa screen and up-regulated DEGs between tumor and normal tissues in liver. C Heatmap displayed expression level of these 13 genes in HCC and normal tissues. D KEGG pathways of these 13 genes were rank-ordered by enrichment ratio. E Forest plot of P value and HR for 13 sorafenib DS-related genes. P < 0.05 was considered statistically significant. Protective factor: HR < 1; Risk factor: HR > 1. F LASSO regression analysis of these 5 sorafenib DS-related prognostic genes. Red dots representing partial likelihood deviance values and error bars representing standard error (SE). The left and right dotted lines represented optimal values by minimum criteria and 1SE criteria, respectively. G LASSO coefficient profiles of the 5 sorafenib DS-related prognostic genes. H Left: flowchart for prognostic model establishment. Right: the distributions of risk score and survival status of 5 sorafenib DS-related prognosis signature genes for TCGA-LIHC dataset. I Heatmap showed high expression of 5 sorafenib DS-related prognostic genes in high-risk populations. J Violin plot compared risk score between High-risk and Low-risk patients
    Rn1 Ssdna Oligo Pools, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/Oligo+Pools/bio_rxiv__64898__2026__10__16__759746-156-2-9
    Average 99 stars, based on 1 article reviews
    rn1 ssdna oligo pools - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    95
    Twist Bioscience oligo library
    Schematic of cloning strategy for <t>paired</t> <t>pegRNA</t> library programming 18,380 deletions. Our early attempts resulted in frequent cassette deletions during the second round of cloning when introducing an H1 promoter for the second pegRNA. These cassette deletions were likely a consequence of the perfect homology of the pegRNA scaffold sequence. To mitigate this, the <t>oligo</t> pool was first cloned into pUC19 (“Step 1”) and subsequently PCR-linearized to add Gibson homology arms for the second cloning step (“Step 2”). This second round of cloning introduced the PEMV pseudoknot for pegRNA1 and the H1 promoter for pegRNA2 (“Step 3”). After Gibson assembly, the paired pegRNA cassette was PCR-linearized and size-selected for full-length cassettes before insertion into the final piggyBac destination vector, which contains a U6 promoter for pegRNA1 and an evoPreQ1 sequence for pegRNA2.
    Oligo Library, supplied by Twist Bioscience, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pools/Cloned+Oligo+Pool+Library/bio_rxiv__64898__2026__10__13__758960-252-1-3
    Average 95 stars, based on 1 article reviews
    oligo library - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    (A) Barcode level CD8 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD8 + screen. (B) and (C) CD4 + log 2 fold change relative to the frequency in the plasmid pool (Day −10) vs. time for bZIP variants significantly enriched (B) or de-enriched (C) in CD8 + T cells. Log 2 fold change fit by n = 2 donors, 2 replicates and calculated via DESeq2; significance calculated via Wald test in DESeq2. Open circles indicate timepoints with p adj < 0.05. (D) Barcode level CD4 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD4 + screen. The results from one bZIP screen replicate on two donors are shown in (A) and (D).

    Journal: bioRxiv

    Article Title: A network of bZIP transcription factors and inhibitors enforces differentially proliferative and cytotoxic states in T cells

    doi: 10.64898/2026.10.28.762687

    Figure Lengend Snippet: (A) Barcode level CD8 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD8 + screen. (B) and (C) CD4 + log 2 fold change relative to the frequency in the plasmid pool (Day −10) vs. time for bZIP variants significantly enriched (B) or de-enriched (C) in CD8 + T cells. Log 2 fold change fit by n = 2 donors, 2 replicates and calculated via DESeq2; significance calculated via Wald test in DESeq2. Open circles indicate timepoints with p adj < 0.05. (D) Barcode level CD4 + log 2 fold change (Day 15 vs. Plasmid) values (red bars) for variants significantly enriched or de-enriched in the CD8 + screen. The grey gradient in the background shows the distribution of all barcodes in the CD4 + screen. The results from one bZIP screen replicate on two donors are shown in (A) and (D).

    Article Snippet: Live CD8 and CD4 CAR(tCD19) + NGFR + T cell pools were collected using a Sony SH800 on day −4 (day 6 of expansion), 0, 9, and 15 of the coculture.

    Techniques: Plasmid Preparation

    (A) Fold-change expansion of TF-overexpressing CAR T cells; n = 4-5 donors; error bars show SD; significance calculated via two-way ANOVA with Tukey’s test for multiple comparisons; **** p < 0.0001, *** p < 0.001 (B) Fold-change residual tumor relative to the tumor cells added for each round of stimulation; n = 5 donors; error bars show SD (C) Frequency of TNF-α + , IFN-γ + , GNLY + , and IL-2 + TF-overexpressing GD2 CAR T cells at baseline and after 3 rounds of chronic tumor cell stimulation; n = 4-5 donors; error bars show SD; significance calculated via one-way ANOVA with Dunnett’s test for multiple comparisons; **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05. (D) UMAPs for paired BATF2 conditions per timepoint. Pie charts display the frequency of each FLOWSOM cluster. Cluster colors are the same as in . (E) Frequency of CD25 + cells for CD8+ (left) and CD4+ (right) GD2 CAR T cells in coculture; n = 5 donors; error bars show SD; significance calculated via two-way ANOVA with Dunnett’s multiple comparison’s test; **** p < 0.0001, *** p < 0.001. (F) Overall frequency of CD4 + BATF2-overexpressing GD2 CAR T cells in coculture (G) Expression of select markers in BATF2-overexpressing and CAR.tNGFR T cells in coculture; n = 5 donors; error bars show SD; significance calculated via mixed-effects model for the effect of condition; *** p < 0.001. (H) CCR7 + frequency in CD8 + CAR.BATF2 and CAR.tNGFR T cells (I) Fold-change expansion of TF-overexpressing GD2 CAR T cells cultured with or without IL-7 and IL-15 for 7 days

    Journal: bioRxiv

    Article Title: A network of bZIP transcription factors and inhibitors enforces differentially proliferative and cytotoxic states in T cells

    doi: 10.64898/2026.10.28.762687

    Figure Lengend Snippet: (A) Fold-change expansion of TF-overexpressing CAR T cells; n = 4-5 donors; error bars show SD; significance calculated via two-way ANOVA with Tukey’s test for multiple comparisons; **** p < 0.0001, *** p < 0.001 (B) Fold-change residual tumor relative to the tumor cells added for each round of stimulation; n = 5 donors; error bars show SD (C) Frequency of TNF-α + , IFN-γ + , GNLY + , and IL-2 + TF-overexpressing GD2 CAR T cells at baseline and after 3 rounds of chronic tumor cell stimulation; n = 4-5 donors; error bars show SD; significance calculated via one-way ANOVA with Dunnett’s test for multiple comparisons; **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05. (D) UMAPs for paired BATF2 conditions per timepoint. Pie charts display the frequency of each FLOWSOM cluster. Cluster colors are the same as in . (E) Frequency of CD25 + cells for CD8+ (left) and CD4+ (right) GD2 CAR T cells in coculture; n = 5 donors; error bars show SD; significance calculated via two-way ANOVA with Dunnett’s multiple comparison’s test; **** p < 0.0001, *** p < 0.001. (F) Overall frequency of CD4 + BATF2-overexpressing GD2 CAR T cells in coculture (G) Expression of select markers in BATF2-overexpressing and CAR.tNGFR T cells in coculture; n = 5 donors; error bars show SD; significance calculated via mixed-effects model for the effect of condition; *** p < 0.001. (H) CCR7 + frequency in CD8 + CAR.BATF2 and CAR.tNGFR T cells (I) Fold-change expansion of TF-overexpressing GD2 CAR T cells cultured with or without IL-7 and IL-15 for 7 days

    Article Snippet: Live CD8 and CD4 CAR(tCD19) + NGFR + T cell pools were collected using a Sony SH800 on day −4 (day 6 of expansion), 0, 9, and 15 of the coculture.

    Techniques: Cell Stimulation, Expressing, Cell Culture

    CRISPRa integration with TCGA TARGET GTEx database for identifying sorafenib DS-related genes and constructing a novel prognostic signature. A Schematic outline of the CRISPRa screen. SNU387 cells were infected with lenti-MPHv2 lentivirus and then selected with hygromycin (200 µg/mL). Subsequently, the library containing cell pool was constructed by infecting with the SAM libraries lentivirus at an MOI = 0.3 and selecting with blasticidin (3 µg/mL). The cell pool was treated with DMSO or sorafenib (7µM) and 2 weeks post-treatment, surviving cells were subjected to NGS to identify the relative enrichment or depletion of sgRNAs between two groups. B Venn plot showed the intersections genes between top 200 positive selection from CRISPRa screen and up-regulated DEGs between tumor and normal tissues in liver. C Heatmap displayed expression level of these 13 genes in HCC and normal tissues. D KEGG pathways of these 13 genes were rank-ordered by enrichment ratio. E Forest plot of P value and HR for 13 sorafenib DS-related genes. P < 0.05 was considered statistically significant. Protective factor: HR < 1; Risk factor: HR > 1. F LASSO regression analysis of these 5 sorafenib DS-related prognostic genes. Red dots representing partial likelihood deviance values and error bars representing standard error (SE). The left and right dotted lines represented optimal values by minimum criteria and 1SE criteria, respectively. G LASSO coefficient profiles of the 5 sorafenib DS-related prognostic genes. H Left: flowchart for prognostic model establishment. Right: the distributions of risk score and survival status of 5 sorafenib DS-related prognosis signature genes for TCGA-LIHC dataset. I Heatmap showed high expression of 5 sorafenib DS-related prognostic genes in high-risk populations. J Violin plot compared risk score between High-risk and Low-risk patients

    Journal: BMC Cancer

    Article Title: CRISPR screening-informed liver cancer stratification identifies ciclesonide as a novel adjuvant drug to alleviate sorafenib resistance

    doi: 10.1186/s12885-026-17205-6

    Figure Lengend Snippet: CRISPRa integration with TCGA TARGET GTEx database for identifying sorafenib DS-related genes and constructing a novel prognostic signature. A Schematic outline of the CRISPRa screen. SNU387 cells were infected with lenti-MPHv2 lentivirus and then selected with hygromycin (200 µg/mL). Subsequently, the library containing cell pool was constructed by infecting with the SAM libraries lentivirus at an MOI = 0.3 and selecting with blasticidin (3 µg/mL). The cell pool was treated with DMSO or sorafenib (7µM) and 2 weeks post-treatment, surviving cells were subjected to NGS to identify the relative enrichment or depletion of sgRNAs between two groups. B Venn plot showed the intersections genes between top 200 positive selection from CRISPRa screen and up-regulated DEGs between tumor and normal tissues in liver. C Heatmap displayed expression level of these 13 genes in HCC and normal tissues. D KEGG pathways of these 13 genes were rank-ordered by enrichment ratio. E Forest plot of P value and HR for 13 sorafenib DS-related genes. P < 0.05 was considered statistically significant. Protective factor: HR < 1; Risk factor: HR > 1. F LASSO regression analysis of these 5 sorafenib DS-related prognostic genes. Red dots representing partial likelihood deviance values and error bars representing standard error (SE). The left and right dotted lines represented optimal values by minimum criteria and 1SE criteria, respectively. G LASSO coefficient profiles of the 5 sorafenib DS-related prognostic genes. H Left: flowchart for prognostic model establishment. Right: the distributions of risk score and survival status of 5 sorafenib DS-related prognosis signature genes for TCGA-LIHC dataset. I Heatmap showed high expression of 5 sorafenib DS-related prognostic genes in high-risk populations. J Violin plot compared risk score between High-risk and Low-risk patients

    Article Snippet: To ensure adequate library coverage, we maintained a library coverage of > 500 cells per sgRNA, as recommended [ ].Next, we treated the cell pool with DMSO as control group and sorafenib (7 μM, MedChemExpress, # 284461-73-0) as experimental group for 2 weeks.We performed three independent biological replicates ( n = 3) for both the DMSO control and sorafenib groups in the CRISPRa screen.

    Techniques: Infection, Construct, Selection, Expressing, Analysis

    The signature showed a significant correlation with unfavorable clinical outcomes. Kaplan-Meier analysis indicated that the OS ( A ) and DSS ( B ) in the High-risk group and the Low-risk group. C The ROC curve of the five-gene signature for 1-, 3- and 5- year OS in TCGA-LIHC. Validation the signature in ICGC-US dataset with expression profiles ( D ), OS ( E ) and ROC curve ( F ). ( G ) Correlation analysis between the risk score of TCGA-LIHC patient and the expression level of sorafenib insensitivity genes. R, the numbers and cycle size all represent correlation coefficient. *: P < 0.05; **: P < 0.01; ***: P < 0.001. H Predicting therapeutic response to sorafenib between two groups. Correlation analysis ( I ) and predicting therapeutic response to sorafenib ( J ) were validated in ICGC-US dataset

    Journal: BMC Cancer

    Article Title: CRISPR screening-informed liver cancer stratification identifies ciclesonide as a novel adjuvant drug to alleviate sorafenib resistance

    doi: 10.1186/s12885-026-17205-6

    Figure Lengend Snippet: The signature showed a significant correlation with unfavorable clinical outcomes. Kaplan-Meier analysis indicated that the OS ( A ) and DSS ( B ) in the High-risk group and the Low-risk group. C The ROC curve of the five-gene signature for 1-, 3- and 5- year OS in TCGA-LIHC. Validation the signature in ICGC-US dataset with expression profiles ( D ), OS ( E ) and ROC curve ( F ). ( G ) Correlation analysis between the risk score of TCGA-LIHC patient and the expression level of sorafenib insensitivity genes. R, the numbers and cycle size all represent correlation coefficient. *: P < 0.05; **: P < 0.01; ***: P < 0.001. H Predicting therapeutic response to sorafenib between two groups. Correlation analysis ( I ) and predicting therapeutic response to sorafenib ( J ) were validated in ICGC-US dataset

    Article Snippet: To ensure adequate library coverage, we maintained a library coverage of > 500 cells per sgRNA, as recommended [ ].Next, we treated the cell pool with DMSO as control group and sorafenib (7 μM, MedChemExpress, # 284461-73-0) as experimental group for 2 weeks.We performed three independent biological replicates ( n = 3) for both the DMSO control and sorafenib groups in the CRISPRa screen.

    Techniques: Analysis, Biomarker Discovery, Expressing, Clinical Proteomics

    Prediction candidate drugs to enhance the antitumor activity of sorafenib basing on DEGs. A Volcano plot of DEGs analysis between top 25%-risk group and bottom 25%-risk group. B The top 10 GO terms ordered by P value were enriched by the first 300 up-regulated and the first 300 down-regulated DEGs between top 25%-risk group and bottom 25%-risk group. C The KEGG circle displayed the logFC scatter map of these selected DEGs. The height of the bar plot of the inner ring indicates the significance of the term (P value), and color corresponds to the z-score representing expression of the enrichment pathway. D Flow chart of the drug perturbation Gene Set Enrichment Analysis (dpGSEA) enrichment approach. E Scatter plot showed the screened drugs by dpGSEA. Red plots represent positively identified drugs with P < 0.05

    Journal: BMC Cancer

    Article Title: CRISPR screening-informed liver cancer stratification identifies ciclesonide as a novel adjuvant drug to alleviate sorafenib resistance

    doi: 10.1186/s12885-026-17205-6

    Figure Lengend Snippet: Prediction candidate drugs to enhance the antitumor activity of sorafenib basing on DEGs. A Volcano plot of DEGs analysis between top 25%-risk group and bottom 25%-risk group. B The top 10 GO terms ordered by P value were enriched by the first 300 up-regulated and the first 300 down-regulated DEGs between top 25%-risk group and bottom 25%-risk group. C The KEGG circle displayed the logFC scatter map of these selected DEGs. The height of the bar plot of the inner ring indicates the significance of the term (P value), and color corresponds to the z-score representing expression of the enrichment pathway. D Flow chart of the drug perturbation Gene Set Enrichment Analysis (dpGSEA) enrichment approach. E Scatter plot showed the screened drugs by dpGSEA. Red plots represent positively identified drugs with P < 0.05

    Article Snippet: To ensure adequate library coverage, we maintained a library coverage of > 500 cells per sgRNA, as recommended [ ].Next, we treated the cell pool with DMSO as control group and sorafenib (7 μM, MedChemExpress, # 284461-73-0) as experimental group for 2 weeks.We performed three independent biological replicates ( n = 3) for both the DMSO control and sorafenib groups in the CRISPRa screen.

    Techniques: Activity Assay, Analysis, Expressing, Gene Set Enrichment Analysis, Significance Assay

    Ciclesonide may improve the antitumor activity of sorafenib with potential involvement of cell cycle regulation in HCC. A Flowchart of RNA Sequencing. B Volcano plot of differentially expressed genes between the ciclesonide group and the control group. C KEGG enrichment analysis showed top 10 pathways enriched by down-regulated genes in ciclesonide-treated group. D Forest plot: prognostic analysis identified 15 cell proliferation-related genes associated with poor prognosis in HCC patients. E Heatmap displayed expression level of 15 cell proliferation-related genes in HCC and normal tissues. F GSEA shows cell cycle was down-regulated under ciclesonide treatment. P value and normalized enrichment scores (NES) are labeled. G Violin plot compared cell cycle pathway score between high score group and low score group. H Kaplan-Meier analysis indicated the OS in the high score group and the low score group

    Journal: BMC Cancer

    Article Title: CRISPR screening-informed liver cancer stratification identifies ciclesonide as a novel adjuvant drug to alleviate sorafenib resistance

    doi: 10.1186/s12885-026-17205-6

    Figure Lengend Snippet: Ciclesonide may improve the antitumor activity of sorafenib with potential involvement of cell cycle regulation in HCC. A Flowchart of RNA Sequencing. B Volcano plot of differentially expressed genes between the ciclesonide group and the control group. C KEGG enrichment analysis showed top 10 pathways enriched by down-regulated genes in ciclesonide-treated group. D Forest plot: prognostic analysis identified 15 cell proliferation-related genes associated with poor prognosis in HCC patients. E Heatmap displayed expression level of 15 cell proliferation-related genes in HCC and normal tissues. F GSEA shows cell cycle was down-regulated under ciclesonide treatment. P value and normalized enrichment scores (NES) are labeled. G Violin plot compared cell cycle pathway score between high score group and low score group. H Kaplan-Meier analysis indicated the OS in the high score group and the low score group

    Article Snippet: To ensure adequate library coverage, we maintained a library coverage of > 500 cells per sgRNA, as recommended [ ].Next, we treated the cell pool with DMSO as control group and sorafenib (7 μM, MedChemExpress, # 284461-73-0) as experimental group for 2 weeks.We performed three independent biological replicates ( n = 3) for both the DMSO control and sorafenib groups in the CRISPRa screen.

    Techniques: Activity Assay, RNA Sequencing, Control, Analysis, Expressing, Labeling, Significance Assay

    Combined sorafenib and ciclesonide treatment augments HCC sensitivity to sorafenib. Cell viability was quantified by CCK-8. The results were shown as mean ± SD from four independent experiments. A Response of liver cancer cells (SNU387, SK-HEP-1, HEPG2 and Huh7) to sorafenib in vitro. B SNU387 cells were grown in the absence or presence of ciclesonide at the indicated concentrations (0, 5, 10, 20, 40µM) for 48 h. C SNU387 cells were treated with the ciclesonide (20µM) ± sorafenib (6µM) for 48 h. D SNU387 cells were cultured with ciclesonide at the indicated concentrations (0, 5, 10, 20, 40µM) + sorafenib (6µM) for 48 h. E SNU387 cells were treated with ciclesonide (20µM) ± sorafenib (6µM) and measured at 0, 24, 48, 72 h. F Ciclesonide (10µM), sorafenib (6µM) and the combination treatment inhibit colonies. G Effect of combined sorafenib (20 mg/kg) and ciclesonide (20 mg/kg) treatment on the volume and weight of HCC cells in a xenograft mouse model. The number of observed colonies were counted manually for each group. The results were shown as mean ± SD from three independent experiments. ***: P < 0.001, ****: P < 0.0001

    Journal: BMC Cancer

    Article Title: CRISPR screening-informed liver cancer stratification identifies ciclesonide as a novel adjuvant drug to alleviate sorafenib resistance

    doi: 10.1186/s12885-026-17205-6

    Figure Lengend Snippet: Combined sorafenib and ciclesonide treatment augments HCC sensitivity to sorafenib. Cell viability was quantified by CCK-8. The results were shown as mean ± SD from four independent experiments. A Response of liver cancer cells (SNU387, SK-HEP-1, HEPG2 and Huh7) to sorafenib in vitro. B SNU387 cells were grown in the absence or presence of ciclesonide at the indicated concentrations (0, 5, 10, 20, 40µM) for 48 h. C SNU387 cells were treated with the ciclesonide (20µM) ± sorafenib (6µM) for 48 h. D SNU387 cells were cultured with ciclesonide at the indicated concentrations (0, 5, 10, 20, 40µM) + sorafenib (6µM) for 48 h. E SNU387 cells were treated with ciclesonide (20µM) ± sorafenib (6µM) and measured at 0, 24, 48, 72 h. F Ciclesonide (10µM), sorafenib (6µM) and the combination treatment inhibit colonies. G Effect of combined sorafenib (20 mg/kg) and ciclesonide (20 mg/kg) treatment on the volume and weight of HCC cells in a xenograft mouse model. The number of observed colonies were counted manually for each group. The results were shown as mean ± SD from three independent experiments. ***: P < 0.001, ****: P < 0.0001

    Article Snippet: To ensure adequate library coverage, we maintained a library coverage of > 500 cells per sgRNA, as recommended [ ].Next, we treated the cell pool with DMSO as control group and sorafenib (7 μM, MedChemExpress, # 284461-73-0) as experimental group for 2 weeks.We performed three independent biological replicates ( n = 3) for both the DMSO control and sorafenib groups in the CRISPRa screen.

    Techniques: Sensitivity, CCK-8 Assay, In Vitro, Cell Culture, Xenograft Assay

    Schematic of cloning strategy for paired pegRNA library programming 18,380 deletions. Our early attempts resulted in frequent cassette deletions during the second round of cloning when introducing an H1 promoter for the second pegRNA. These cassette deletions were likely a consequence of the perfect homology of the pegRNA scaffold sequence. To mitigate this, the oligo pool was first cloned into pUC19 (“Step 1”) and subsequently PCR-linearized to add Gibson homology arms for the second cloning step (“Step 2”). This second round of cloning introduced the PEMV pseudoknot for pegRNA1 and the H1 promoter for pegRNA2 (“Step 3”). After Gibson assembly, the paired pegRNA cassette was PCR-linearized and size-selected for full-length cassettes before insertion into the final piggyBac destination vector, which contains a U6 promoter for pegRNA1 and an evoPreQ1 sequence for pegRNA2.

    Journal: bioRxiv

    Article Title: Multiplex programming of mappable, molecularly tagged genomic deletions

    doi: 10.64898/2026.10.13.758960

    Figure Lengend Snippet: Schematic of cloning strategy for paired pegRNA library programming 18,380 deletions. Our early attempts resulted in frequent cassette deletions during the second round of cloning when introducing an H1 promoter for the second pegRNA. These cassette deletions were likely a consequence of the perfect homology of the pegRNA scaffold sequence. To mitigate this, the oligo pool was first cloned into pUC19 (“Step 1”) and subsequently PCR-linearized to add Gibson homology arms for the second cloning step (“Step 2”). This second round of cloning introduced the PEMV pseudoknot for pegRNA1 and the H1 promoter for pegRNA2 (“Step 3”). After Gibson assembly, the paired pegRNA cassette was PCR-linearized and size-selected for full-length cassettes before insertion into the final piggyBac destination vector, which contains a U6 promoter for pegRNA1 and an evoPreQ1 sequence for pegRNA2.

    Article Snippet: The oligo library (Twist Bioscience), encoding 18,380 paired pegRNA deletion designs was PCR amplified (NEBNext Ultra II Q5 Master Mix, NEB, M0544L) using primers adding Gibson homology arms for cloning into pUC19; PCR amplification was performed for 10 cycles with primers oligo_1 + oligo_2 and PCR products were purified with a 1× AMPure XP bead cleanup (Beckman Coulter, A63882) and eluted in water.

    Techniques: Cloning, Sequencing, Clone Assay, Gibson Assembly, Plasmid Preparation

    (A) Schematic of the cloning strategy for the secondary screen’s paired-pegRNA library. Each pegRNA uses a distinct, non-repetitive scaffold sequence to reduce swapping and inter-oligo deletions. The oligo pool was synthesized with homology arms matching the destination vector, enabling direct Gibson assembly into the piggyBAC backbone, which contains a U6 promoter driving pegRNA1 and an evoPreQ1 tail fused to pegRNA2 (“Step 1”). The programmed cloning cassette includes BbsI restriction sites positioned to allow scarless insertion of an evoPreQ1 sequence downstream of pegRNA1 and an H1 promoter upstream of pegRNA2 (“Steps 2-3”). (B) Schematic of targeting negative-control pegRNA pair design using 27 previously validated PE spacer sequences targeting 19 genes. For each of these spacer/PBS sequences, the two RT templates (programmed insertions) that would normally be encoded on the top- and bottom-strand pegRNAs of an enhancer-targeting pair were instead programmed using the same spacer/PBS. As a result, any observed editing signal should reflect single–pegRNA insertion events rather than paired deletion events. (C) Schematic of non-targeting negative-control pegRNA pair design. Non-targeting spacer sequences were randomly paired (n = 100) and used to construct pegRNA pairs encoding the same RT templates (programmed insertions) as those encoded by cCRE-targeting pegRNA pairs. (D) Positional profile of soft-clipping frequency along Read 1. The fraction of reads exhibiting a soft-clipped base at each position is plotted, showing where along the read soft-clipping events are most enriched. Because inter-cassette deletions span the Read 1 region, they manifest as soft-clipped alignments in Read 1. The first 10 bp of the read correspond to a UMI which is expected to be softclipped from the alignment. (E) Distribution of 3′ soft-clipped lengths in Read 1. Bars represent the percentage of reads with a given soft-clip length at the 3′ end. The first 10 bp of each read correspond to the UMI sequence and are therefore expected to be soft-clipped. (F) Estimation of swapping rates in the final cloned pegRNA library. Sequencing read 1 was mapped to pegRNA1, and read 2 was mapped to pegRNA2. Reads were filtered to retain only high-quality alignments with complete/expected CIGAR strings. Filtered read pairs in which both mates aligned to the same reference were counted as valid pairs, while read pairs that passed filtering but had mismatched references were classified as swapped pairs. Bars show the percentage of read pairs in each category. (G) Composition of valid pegRNA pairs in the final library. Among all read pairs confirmed as valid (both mates mapping to the same element), reads corresponding to NTC pegRNA pairs, TNC pegRNA pairs, and targeting pegRNA pairs were quantified. Bars show the relative abundance of each category as a percentage of total valid pairs. (H) Abundance distribution of valid pegRNA pairs. For NTC pairs, TNC pairs, and targeting pairs, elements were ranked by read count within each group and plotted as ranked percentile (x-axis) versus log10(read count) (y-axis). Points show the per-element abundance distributions for each category (colors).

    Journal: bioRxiv

    Article Title: Multiplex programming of mappable, molecularly tagged genomic deletions

    doi: 10.64898/2026.10.13.758960

    Figure Lengend Snippet: (A) Schematic of the cloning strategy for the secondary screen’s paired-pegRNA library. Each pegRNA uses a distinct, non-repetitive scaffold sequence to reduce swapping and inter-oligo deletions. The oligo pool was synthesized with homology arms matching the destination vector, enabling direct Gibson assembly into the piggyBAC backbone, which contains a U6 promoter driving pegRNA1 and an evoPreQ1 tail fused to pegRNA2 (“Step 1”). The programmed cloning cassette includes BbsI restriction sites positioned to allow scarless insertion of an evoPreQ1 sequence downstream of pegRNA1 and an H1 promoter upstream of pegRNA2 (“Steps 2-3”). (B) Schematic of targeting negative-control pegRNA pair design using 27 previously validated PE spacer sequences targeting 19 genes. For each of these spacer/PBS sequences, the two RT templates (programmed insertions) that would normally be encoded on the top- and bottom-strand pegRNAs of an enhancer-targeting pair were instead programmed using the same spacer/PBS. As a result, any observed editing signal should reflect single–pegRNA insertion events rather than paired deletion events. (C) Schematic of non-targeting negative-control pegRNA pair design. Non-targeting spacer sequences were randomly paired (n = 100) and used to construct pegRNA pairs encoding the same RT templates (programmed insertions) as those encoded by cCRE-targeting pegRNA pairs. (D) Positional profile of soft-clipping frequency along Read 1. The fraction of reads exhibiting a soft-clipped base at each position is plotted, showing where along the read soft-clipping events are most enriched. Because inter-cassette deletions span the Read 1 region, they manifest as soft-clipped alignments in Read 1. The first 10 bp of the read correspond to a UMI which is expected to be softclipped from the alignment. (E) Distribution of 3′ soft-clipped lengths in Read 1. Bars represent the percentage of reads with a given soft-clip length at the 3′ end. The first 10 bp of each read correspond to the UMI sequence and are therefore expected to be soft-clipped. (F) Estimation of swapping rates in the final cloned pegRNA library. Sequencing read 1 was mapped to pegRNA1, and read 2 was mapped to pegRNA2. Reads were filtered to retain only high-quality alignments with complete/expected CIGAR strings. Filtered read pairs in which both mates aligned to the same reference were counted as valid pairs, while read pairs that passed filtering but had mismatched references were classified as swapped pairs. Bars show the percentage of read pairs in each category. (G) Composition of valid pegRNA pairs in the final library. Among all read pairs confirmed as valid (both mates mapping to the same element), reads corresponding to NTC pegRNA pairs, TNC pegRNA pairs, and targeting pegRNA pairs were quantified. Bars show the relative abundance of each category as a percentage of total valid pairs. (H) Abundance distribution of valid pegRNA pairs. For NTC pairs, TNC pairs, and targeting pairs, elements were ranked by read count within each group and plotted as ranked percentile (x-axis) versus log10(read count) (y-axis). Points show the per-element abundance distributions for each category (colors).

    Article Snippet: The oligo library (Twist Bioscience), encoding 18,380 paired pegRNA deletion designs was PCR amplified (NEBNext Ultra II Q5 Master Mix, NEB, M0544L) using primers adding Gibson homology arms for cloning into pUC19; PCR amplification was performed for 10 cycles with primers oligo_1 + oligo_2 and PCR products were purified with a 1× AMPure XP bead cleanup (Beckman Coulter, A63882) and eluted in water.

    Techniques: Cloning, Sequencing, Synthesized, Plasmid Preparation, Gibson Assembly, Negative Control, Construct, Clone Assay